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Emerging evidence indicates that impaired mitochon-
drial fatty acid -oxidation plays a key role in liver
steatosis. We have recently demonstrated that in-
creased angiotensin (ANG) II causes progressive he-
patic steatosis associated with oxidative stress; how-
ever, the underlying mechanisms remain unclear. We
hypothesized that ANG II causes hepatic mitochon-
drial oxidative damage and impairs mitochondrial
-oxidation, thereby leading to hepatic steatosis. We
used the Ren2 rat with elevated endogenous ANG II
levels to evaluate mitochondrial ultrastructural
changes, gene expression levels, and -oxidation.
Compared with Sprague-Dawley littermates, Ren2 liv-
ers exhibited mitochondrial damage and reduced
-oxidation, as evidenced by ultrastructural abnor-
malities, decrease of mitochondrial content, percent-
age of palmitate oxidation to CO2, enzymatic activities
(-HAD and citrate synthase), and the expression lev-
els of cytochrome c , cytochrome c oxidase subunit 1,
and mitochondrial transcription factor A. These ab-
normalities were improved with either ANG II recep-
tor blocker valsartan or superoxide dismutase/cata-
lase mimetic tempol treatment. Both valsartan and
tempol substantially attenuated mitochondrial lipid
peroxidation in Ren2 livers. Interestingly, there was
no difference in the expression of key enzymes (ACC1
and FAS) for fatty acid syntheses and their transcrip-
tion factors (SREBP-1c and ChREBP) between Sprague-
Dawley, untreated Ren2, and valsartan- or tempol-
treated Ren2 rats. These results document that ANG
II induces mitochondrial oxidative damage and im-
pairs mitochondrial -oxidation, contributing to
liver steatosis. (Am J Pathol 2009, 174:1329–1337; DOI:
10.2353/ajpath.2009.080697)
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon liver disease in the US and significantly contributes
to premature mortality.1–4 NAFLD represents a wide
spectrum of disorders ranging from liver steatosis, to
steatohepatitis and cirrhosis, and increases the risk for
development of hepatocellular carcinoma.5,6 Importantly,
liver steatosis is the first and critical step in NAFLD, which
may progress to advanced steatohepatitis characterized
by hepatocyte injury, inflammation and fibrosis, and ulti-
mately end-stage cirrhosis.2–4,7 However, the precise
mechanisms for initiation and progression of NAFLD re-
main unclear.
Emerging evidence indicates that oxidative stress and
inflammation may play a fundamental role in the patho-
genesis of NAFLD.2–4 Angiotensin (ANG) II, the primary
component of the renin angiotensin system, has pro-
oxidant, pro-inflammatory, and profibrogenic activities.
ANG II plays an integral role in the pathogenesis of
hypertension.8 Clinical and experimental evidence sug-
gests that ANG II is also implicated in liver disease.9–18
Patients with cirrhosis and rats with active liver fibrogen-
esis exhibit increased systemic ANG II levels and local
hepatic renin angiotensin system activity.11,14 Animals
with liver steatosis have increased expression of ANG II
and ANG II type 1 receptor (AT1R) in the livers.
12,13,17
ANG II inhibition has been shown to attenuate triglyceride
(TG) accumulation in the liver of Zucker obese rats.15,17
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We have recently reported that ANG II causes progres-
sive hepatic steatosis, inflammation, and fibrosis associ-
ated with oxidative stress in a transgenic Ren2 rat model
with elevated endogenous ANG II levels.18 These obser-
vations suggest that ANG II plays a role in the initiation
and progression of NAFLD. However, the underlying
mechanisms of ANG II-induced hepatic TG accumulation
remain to be elucidated. Many factors have been impli-
cated in liver steatosis, increased fatty acid syntheses
through activation of lipogenic pathway and/or decreased
fatty acid oxidation represent two critical mechanisms in
triggering hepatic TG accumulation.2–4
Mitochondrial -oxidation is the major pathway for fatty
acid oxidation. Emerging evidence indicates that im-
paired mitochondrial -oxidation plays a key role in liver
steatosis.4 Mitochondria are rich in proteins and en-
zymes encoded by both nuclear and mitochondrial DNA
(mtDNA). mtDNA is more vulnerable to damage than
nuclear DNA by a variety of pathological insults including
reactive oxygen species (ROS).19 Accordingly, we hy-
pothesize that increased ROS by ANG II causes mito-
chondrial oxidative damage, leading to depletion and/or
reduction of mitochondrial genes and proteins, impaired
mitochondrial -oxidation, and consequently develop-
ment of hepatic steatosis. We further hypothesize that
AT1R blockade and/or antioxidant treatment will attenu-
ate mitochondrial oxidative damage and improve hepatic
mitochondrial gene and protein expression, as well as
hepatic mitochondrial -oxidation in this Ren2 rat model.
Materials and Methods
Animals and Treatment
Male Sprague-Dawley (SD) and transgenic heterozygous
(/) Ren2 rats were received from Wake Forest Univer-
sity School of Medicine (Winston-Salem, NC). All rats
were maintained on Formulab Diet (5008; PMI Nutrition
International, LLC, Brentwood, MO) with free access to
drinking water. SD and Ren2 rats at the age of 9 weeks
were randomly assigned as untreated SD control (SD),
Ren2 control (RC), Ren2 valsartan (RV), and Ren2 tempol
(RT) (six to seven rats in each group). Rats were given
valsartan at 30 mg/kg/day or tempol at 1 mmol/L in their
drinking water or placebo for 3 weeks. All animal proce-
dures followed the University of Missouri Animal Care
and Use Committees and National Institutes of Health
guidelines.
Materials
The AT1R blocker (valsartan) was supplied by Novartis
Pharmaceutical Co. (East Hanover, NJ) and the superox-
ide dismutase (SOD)/catalase mimetic (tempol) was pur-
chased from Sigma-Aldrich Co. (St. Louis, MO). Antibod-
ies against SREBP-1c, ChREBP, FAS, ACC1, CPS1,
MTCO1, cytochrome c, mtTFA were obtained from Cell
Signaling (Danvers, MA), Abcam (Cambridge, MA), BD
Bioscience (San Jose, CA), Santa Cruz Biotechnology
(Santa Cruz, CA), and Upstate (Lake Placid, NY),
respectively.
Transmission Electronic Microscopy
Liver tissues were collected and fixed in 2% glutaralde-
hyde/2% paraformaldehyde, and secondary fixation with
1% osmium tetroxide, embedded in Epon-Spurr’s resin,
sectioned at 85 nm, and stained with uranyl acetate/
Sato’s triple lead stain. Electron microscopy was per-
formed at the University of Missouri–Columbia Electron
Microscopy Core Facility using a JEOL (Tokyo, Japan)
1200-EX transmission electron microscope.
Immunohistochemistry
Liver paraffin sections were deparaffinized and nonspe-
cific antibody binding was blocked with 5% bovine serum
albumin and 5% goat or rabbit serum in phosphate-
buffered saline. These sections were incubated with anti-
CPS1, ChREBP, or SREBP-1c antibodies at 1:200 dilu-
tions for overnight at 4°C. After washing, the sections
were incubated with a second antibody conjugated with
Alexa-486 or -568 for 1 hour at room temperature. The
sections were counterstained with 4,6-diamidino-2-phe-
nylindole (DAPI) (Vector Laboratories, Burlingame, CA)
and mounted with mounting media (Vector Laboratories).
Images were acquired with a fluorescence microscope
(Eclipse 50i; Nikon, Tokyo, Japan).
Measurement of Mitochondrial Oxidative Stress
4-HNE, a by-product of lipid peroxidation and a marker of
oxidative stress, was measured by Western blot. Liver
samples were homogenized using a tissue homogenizer
(Retsch, Newtown, PA) in lysis buffer [50 mmol/L phos-
phate buffer, 0.01 mmol/L ethylenediaminetetraacetic
acid, 1 mmol/L phenylmethyl sulfonyl fluoride, 2 mol/L
leupeptin, and 2 mol/L pepstatin A (pH 7.4)]. The ho-
mogenate was centrifuged at 1000  g for 30 minutes at
4°C, and the supernatant (S1) was further centrifuged at
13,000  g for 20 minutes at 4°C, yielding supernatant
(S2) and a pellet containing mitochondria. Forty g of
protein (mitochondrial fractions) were loaded in a sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to a polyvinylidene difluoride membrane and
probed with anti-4-HNE antibodies (1:1000 dilution)
against 4-HNE-modified proteins. After washing, the
membrane was incubated with horseradish peroxi-
dase-conjugated secondary antibodies (1:10,000 dilu-
tion). The signal was captured using a Phospho-imager
system (Bio-Rad, Hercules, CA) and the intensities of the
immunoblot bands were quantified using Quantity One
software (Bio-Rad). -Actin was used as a loading
control.
SOD Activity
Liver samples were homogenized in a buffer (0.25 mol/L
sucrose, 0.5 mmol/L ethylenediaminetetraacetic acid, 50
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mmol/L HEPES, protease inhibitors, and phosphatase
inhibitors). The homogenate was centrifuged at 1500  g
for 5 minutes at 4°C. The supernatant was used for mea-
suring cytosolic Cu-ZnSOD activity using a commercial
kit (OxisResearch, Foster City, CA). The supernatant was
treated with 2 mmol/L potassium cyanide to inhibit both
Cu/Zn-SOD and extracellular SOD and used for measur-
ing mitochondrial MnSOD activity using a commercial kit
(Cayman Chemical Co., Ann Arbor, MI).
Real-Time Polymerase Chain Reaction (PCR)
Analysis
Total RNA was extracted using an RNA isolation kit (Qia-
gen, Valencia, CA) according to the manufacturer’s in-
structions. Real-time PCR analysis was used to quantify
expression levels of several key genes related to mito-
chondrial function in liver using an ABI Prism 7700 de-
tector (PE Applied Biosciences, Foster City, CA): mito-
chondrial transcription factor A (mtTFA) using primers,
forward: 5-CAAGGGAAATTGAAGCTTGT-3, reverse:
5-CATTTGCTCTTCCCAAGACT-3. Cytochrome c oxi-
dase subunit 1 (MTCO1): forward, 5-AGCAGGAATAG-
TAGGGACAGC-3, reverse, 5-TGAGAGAAGTAGTAG-
GACGGC-3. For the analysis, 100 ng of total RNA were
used, each sample was run in duplicate, and the mean
value was used to calculate the gene expression level.
Gene expression levels were normalized relative to the
expression of housekeeping gene GAPDH.
Western Blot Analysis
Liver samples were homogenized as described above.
Twenty-five g of protein (whole homogenate) were
loaded in a sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to a polyvinylidene diflu-
oride membrane and probed with primary antibodies (1:
1000) against CPS1, mtTFA, MTCO1, cytochrome c, FAS,
ACC1, SREBP, and ChREBP. After washing, the mem-
brane was incubated with horseradish peroxidase-con-
jugated secondary antibodies (1:10,000). The intensities
of the bands were quantified as described above.
Enzyme Activity Assay
Enzyme activity for citrate synthase and -hydroxya-
cyl-CoA dehydrogenase (-HAD) was determined us-
ing a spectrophotometer at a wavelength of 412 nm
and 340 nm, respectively, as described previously
from our group.20 Enzyme activity is expressed as
U/ml/g protein.
Figure 1. Mitochondrial morphology and content in livers from Ren2 and SD rats. A: Representative microphotographs of transmission electron microscopy, Ren2
livers showed big, swollen mitochondria with decreased matrix density compared with SD rats. M, mitochondria; L, lipid droplet. B: Representative immuno-
fluorescence (IF) images showed decreased CPS1 (red) in Ren2 liver sections compared with SD controls. DAPI staining (blue) for nuclei. C: Representative
immunoblot analyses for CPS1 (top) and bars representing band densitometry (bottom). D: Representative immunoblot analyses for 4-HNE (top) and bars
representing band densitometry (bottom). E: Enzyme activities for cytosolic SOD (cu-znSOD) and mitochondrial SOD (mnSOD). The results are mean  SEM
for five rats for each group, *P  0.01 and **P  0.05 Ren2 versus SD. Scale bars: 200 nm (A); 10 m (B). Original magnifications: 25,000 (A); 400 (B).
Angiotensin II and Fatty Liver Disease 1331
AJP April 2009, Vol. 174, No. 4
Fatty Acid Oxidation
Fatty acid oxidation was measured in the liver homoge-
nate preparation as described previously from our
group.20 The oxidation rate of [14C]palmitate was mea-
sured by collecting and counting the 14CO2 and acid-
soluble metabolites produced during incubation in a
sealed trapping device. Palmitate (200 mol/L) and
[1-14C]palmitate were bound to 0.5% bovine serum albu-
min (final concentration) at 37°C and brought up in reac-
tion buffer to yield the following final concentrations: 100
mmol/L sucrose, 10 mmol/L Tris-HCl, 10 mmol/L KPO4,
100 mmol/L KCl, 1 mmol/L 4MgCl2  6H2O, 1 mmol/L
L-carnitine, 0.1 mmol/L malate, 2 mmol/L ATP, 0.05
mmol/L CoA, and 1 mmol/L dithiothreitol (pH 7.4). Reac-
tion buffer (320 l) was added to 80 l of liver homoge-
nate prepared in a sucrose-ethylenediaminetetraacetic
acid buffer in the well of the trapping device. A 0.65-ml
centrifuge tube containing 400 l of NaOH also was
inserted in the well followed by sealing the well with a
rubber gasket. After 60 minutes of incubation at 37°C on
an orbital shaker, 200 l of 70% perchloric acid were
injected through the rubber gasket into the bottom of the
well. 14CO2 driven out of the reaction by the perchloric
acid during another 60-minute incubation was trapped in
the NaOH and then counted on a scintillation counter.
The remaining homogenate was centrifuged at 18,000
rpm for 20 minutes and a sample of the resulting super-
natant (acid soluble metabolites) also was counted on a
scintillation counter. Specific activity was taken by count-
ing a portion of the reaction buffer.
Statistical Analysis
All data are reported as the means  SEM. One-way
analysis of variance test and Student’s t-test were used to
determine the significance among groups. A value of P
0.05 was considered to be statistically significant.
Results
ANG II Contributes to Mitochondrial Damage in
Ren2 Liver
We have recently demonstrated that Ren2 rats develop
progressive hepatic steatosis.18 Mitochondria play an
integral role in lipid metabolism and homeostasis. To
determine whether ANG II-induced hepatic steatosis is
associated with mitochondrial damage, mitochondrial ul-
trastructure was assessed by transmission electronic mi-
croscopy, and mitochondrial content was determined by
immunostaining and Western blot using an antibody
against a hepatic mitochondrial marker carbamoyl-phos-
phate synthase (CPS)-1. Transmission electron micro-
scopy analysis revealed mitochondrial ultrastructural ab-
normalities (swollen and reduced matrix density) in Ren2
livers compared with SD controls (Figure 1A). Immuno-
staining showed decreased CPS1 staining in Ren2 livers
compared with SD rats (Figure 1B). Western blotting
further corroborated significant reductions of CPS1 pro-
tein levels in Ren2 livers compared with SD (Figure 1C,
P  0.01).
In an earlier report, we have documented that ANG II
induces NADPH oxidase activation and increases ROS for-
mation in Ren2 livers.18 To further determine whether in-
creased ROS production contributes to mitochondrial oxi-
dative stress, which in turn results in the mitochondrial
abnormalities observed in Ren2 livers, mitochondrial frac-
tions were insolated and lipid peroxidation was determined
by measuring oxidative stress marker 4-HNE levels using
Western blot analysis. Ren2 livers exhibited dramatically
increased 4-HNE levels compared with SD controls (Fig-
ure 1D, P  0.05). We further analyzed the activities of
cytosolic SOD (Cu-ZnSOD) and mitochondrial SOD (Mn-
SOD). Interestingly, Cu-ZnSOD, but not MnSOD activity,
in Ren2 livers was markedly decreased compared with
SD controls (Figure 1E).
ANG II Contributes to Depletion of Mitochondrial
Genes and Proteins in Ren2 Liver
We analyzed the hepatic expression of mitochondrial
genes and proteins including cytochrome c and mito-
chondrial cytochrome c oxidase subunit 1 (MTCO1). Ex-
pression of cytochrome c protein was markedly reduced
in Ren2 livers compared with SD (Figure 2A). mRNA and
Figure 2. Hepatic mitochondrial indices and fatty acid -oxidation. A: Rep-
resentative immunoblot for cytochrome c (top) and bar graph for band
densitometry (bottom). B: MTCO1 mRNA expression (normalized to
GAPDH). C: Representative immunoblot for MTCO1 (top) and bar graph for
band densitometry (bottom). D: mtTFA mRNA expression (normalized to
GAPDH). E: Representative immunoblot band for mtTFA (top) and bars
representing band densitometry (bottom). F: Activity of citrate synthase and
-HAD. G: The percentage of palmitate oxidized completely to CO2. The results
are mean  SEM for five rats for each group, *P  0.05, Ren2 versus SD.
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protein levels of MTCO1 were dramatically decreased in
Ren2 livers compared with SD (Figure 2, B and C). Mito-
chondrial transcription factor A (mtTFA), an essential
transcription factor in regulation of mitochondrial genes,
at both mRNA and protein levels, was decreased in Ren2
livers compared with SD livers (Figure 2, D and E).
ANG II Impairs Mitochondrial -Oxidation in
Ren2 Liver
To evaluate mitochondrial fatty acid -oxidation, the ac-
tivities of -hydroxyacyl-CoA dehydrogenase (-HAD)
and citrate synthase were measured and normalized to
protein concentration. -HAD is the rate limiting step for
fatty acid -oxidation in mitochondria. The activities (Fig-
ure 2F) and protein levels (data not shown) of -HAD and
citrate synthase were dramatically decreased in Ren2
livers compared with SD. Mitochondrial fatty acid -oxi-
dation was further determined by measuring the percent-
age of palmitate oxidized completely to CO2. As shown
in Figure 2G, there were markedly reduced palmitate
oxidation in Ren2 livers compared with SD controls
(P  0.05).
ANG II Does Not Affect the Expression of
Lipogenic Enzymes in Ren2 Liver
To determine whether ANG II-induced hepatic steatosis
in Ren2 liver is associated with increased fatty acid syn-
thesis, the key enzyme acetyl-CoA carboxylase (ACC1)
and fatty acid synthase (FAS) as well as their transcrip-
tion factors of SREBP-1c and ChREBP were analyzed by
Western blot. There were no significant differences in the
protein levels of active SREBP-1c (68 kDa, Figure 3A),
total SREBP-1c (125 kDa, data not shown), and ChREBP
(Figure 3C) between SD and Ren2 livers. Immunofluores-
cence revealed a similar staining pattern that SREBP-1c
(Figure 3B) and ChREBP (Figure 3D) were predominantly
located in the cytoplasm with a few stained nuclei in both
Ren2 and SD livers. This further corroborated that there
were comparable protein levels of ACC1 and FAS in
Ren2 and SD livers (Figure 3, E and F).
AT1R Blockade Attenuates Mitochondrial
Damage and Improves Mitochondrial
-Oxidation in Ren2 Liver
The above data suggests that increased ANG II causes
hepatic mitochondrial damage and impairs fatty acid
-oxidation, which contribute to the development of liver
steatosis in the Ren2 rat model. To further determine
whether ANG II inhibition protects hepatic mitochondria
injury and improves mitochondrial -oxidation, 9-week-
old Ren2 rats were treated with the AT1R blocker valsar-
tan for 3 weeks. AT1R blockade attenuated mitochondrial
oxidative stress (Figure 4A), and enhanced cytosolic
Cu-ZnSOD activity (Figure 4B) but not mitochondrial Mn-
SOD activity (Figure 4B) compared with untreated Ren2
livers. Further, AT1R blockade substantially increased
mitochondrial content (Figure 4, C and D), cytochrome c
protein (Figure 5A), MTCO1 mRNA (Figure 5B), MTCO1
protein (Figure 5C), mtTFA mRNA (Figure 5D), and
mtTFA protein (Figure 5E) in treated Ren2 livers com-
pared with untreated Ren2 controls. In addition, valsartan
treatment dramatically attenuated the reduction of the
activities of citrate synthase and -HAD (Figure 5F) and
Figure 3. Hepatic lipogenic transcription factors and enzymes. A: Representative immunoblot for active SREBP-1c (68 kDa, top) and bar graph representing band
densitometry (bottom). B: Representative immunofluorescence images showed that SREBP-1c was predominantly located in cytoplasm (green) and a few nuclei
stained (arrows). C: Representative immunoblot for ChREBP (top) and bar graph representing band densitometry (bottom). D: Immunofluorescence staining
for ChREBP. ChREBP was predominantly located in cytoplasm (green) and a few nuclei stained (arrows). E and F: Representative Western blot bands and
densitometry analysis for ACC1 and FAS. The results of A, C, E, and F are mean  SEM for five rats for each group, there were no significant differences between
Ren2 versus SD controls (P  0.05). No signal was obtained when liver sections were incubated with the secondary antibody only (data not shown). Scale bars 
50 m. Original magnifications, 400.
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the reduction in palmitate -oxidation (Figure 5G) in the
Ren2 livers, in conjunction with attenuation of hepatic ste-
atosis in the Ren2 rats treated with valsartan.18 These re-
sults suggest that ANG II-induced liver steatosis is attribut-
able, at least in part, to ANG II-induced hepatic mitochondrial
damage and impaired mitochondrial -oxidation.
AT1R Blockade Does Not Affect the Expression
of Lipogenic Enzymes in Ren2 Liver
To determine whether AT1R blockade affects the lipo-
genic pathway, ACC1, FAS, SREBP-1c, and ChREBP
were analyzed by Western blot. There were no significant
differences in the protein levels of active SREBP-1c (68
kDa, Figure 6A), total SREBP-1c (125 kDa, data not
shown), and ChREBP (Figure 6B) between valsartan-
treated and untreated Ren2 rats. Immunostaining showed a
similar staining pattern of SREBP-1c and ChREBP in val-
sartan-treated and untreated Ren2 livers (data not
shown). Similarly, there were no significant differences in
the protein levels of ACC1 and FAS between valsartan-
treated and untreated Ren2 rats (Figure 6, C and D).
Tempol Treatment Attenuates Mitochondrial
Damage and Improves Mitochondrial
-Oxidation in Ren2 Liver
To further confirm that ANG II-impaired hepatic mitochon-
drial -oxidation is mediated by oxidative stress, 9-week-old
Ren2 rats were treated with the ROS scavenger tempol
for 3 weeks. Tempol treatment attenuated mitochon-
drial lipid peroxidation (decreased 4-HNE levels) (Fig-
ure 4A), and enhanced cytosolic Cu-ZnSOD activities
(Figure 4B), but not mitochondrial MnSOD activities
(Figure 4B). Tempol treatment preserved mitochondrial
content (Figure 4, C and D), the expression of cyto-
chrome c (Figure 5A), MTCO1 mRNA (Figure 5B),
MTCO1 protein (Figure 5C), mtTFA mRNA (Figure 5D),
and mtTFA protein (Figure 5E) in the Ren2 livers. Tempol
treatment substantially enhanced the activity of citrate
synthase and -HAD (Figure 5F) and palmitate -oxida-
tion (Figure 5G) compared with untreated Ren2 livers. In
addition, as we reported earlier, tempol markedly atten-
uated hepatic steatosis in the Ren2 rat model.18 These
results further suggest that ANG II induces hepatic mito-
chondrial oxidative damage, which in turn impairs mito-
chondrial -oxidation, consequently contributing to liver
steatosis in Ren2 rat model.
Tempol Treatment Does Not Affect the
Expression of Lipogenic Enzymes in Ren2 Liver
To determine whether tempol treatment affects the lipo-
genic pathways, ACC1, FAS, SREBP-1c, andChREBPwere
analyzed by Western blot. Tempol treatment had no effect
on the expression of active SREBP-1c (68 kDa, Figure 6A),
total SREBP-1c (125 kDa, data not shown), and ChREBP
(Figure 6B) compared with untreated Ren2 rats. Immuno-
fluorescence showed a similar staining pattern of SREBP-1c
and ChREBP between tempol-treated and untreated Ren2
livers (data not shown). There were no significant differ-
ences in the protein levels of ACC1 and FAS between
tempol-treated and untreated Ren2 rats (Figure 6, C and D).
Discussion
Recent evidence suggests a strong relationship between
hypertension and NAFLD.21–23 ANG II is known to play a
Figure 4. Effects of valsartan and tempol on hepatic
mitochondrial 4-HNE levels, SOD activity, and mito-
chondrial content. A: Representative immunoblot
analyses for 4-HNE (top) andbars representingband
densitometry (bottom). B: Enzyme activities of cy-
tosolic SOD (Cu-ZnSOD) and mitochondrial SOD
(MnSOD). C: Representative immunofluorescence
microphotographs for mitochondrial marker CPS1
(red) in the liver sections from untreated Ren2 (RC),
valsartan (RV)-, or tempol (RT)-treated Ren2 rats.
DAPI staining (blue) for nuclei. D: Representative
immunoblot analyses for CPS1 (top) and bars rep-
resenting band densitometry (bottom). The results
are mean  SEM for five rats for each group, *P 
0.05 RV or RT versus RC. Scale bars 10 m. Orig-
inal magnifications, 400.
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critical role in the pathogenesis of hypertension. Emerg-
ing evidence indicates that ANG II is also implicated in
the development of NAFLD.12,13,17,18 For instance, ANG
II levels are increased in the liver with fibrosis11,14 and
steatosis.12,13,17 Further, ANG II inhibition ameliorates
hepatic TG accumulation in Zucker obese rats15,17 and
renin angiotensin system-deficient mice are protected
from high-fat diet-induced fatty liver disease.24 ANG II
infusion into normal rats induces hepatic steatosis that is
dependent on the dose and duration of ANG II infu-
sion.16,25 Using a transgenic Ren2 rat model with ele-
vated endogenous ANG II levels, we have recently dem-
onstrated that ANG II causes progressive hepatic
steatosis, inflammation, and fibrosis.18 Furthermore, evi-
dence suggests that ANG II-induced lipid accumulation
in liver is likely to be associated with hepatic insulin
resistance13,26 and oxidative stress.18 An in vivo study
indicates that increased circulating ANG II by infusion
induces hepatic insulin resistance26 whereas inhibition of
ANG II significantly attenuates hepatic insulin resistance
and improves hepatic insulin signaling in animal models
with fatty liver disease.13 Collectively, these observations
suggest that ANG II plays an important role in the patho-
genesis of NAFLD. However, little is known regarding
the mechanisms underlying ANG II-induced hepatic
steatosis.
Our current investigation reveals a novel finding: in-
creased ANG II levels cause mitochondrial oxidative
damage, leading to depletion of mitochondrial genes and
proteins, ultrastructural abnormalities, decreased mito-
chondrial content, and impaired mitochondrial -oxida-
tion. These mitochondrial abnormalities in Ren2 livers
were substantially improved after valsartan or tempol
treatment for 3 weeks. Hence, our results document that
ANG II-mediated ROS formation induces mitochondrial
abnormalities leading to reduced fatty acid oxidation,
thereby contributing to the development of NAFLD. To
our knowledge, this is the first study to report that ANG II
induces hepatic mitochondrial oxidative damage and
impairs mitochondrial -oxidation, leading to ANG II-
induced hepatic steatosis. Our results further extend
our understanding that that NAFLD is a mitochondrial
disease.4,27–29 Indeed, patients and animals with
NAFLD exhibit hepatic mitochondrial abnormalities at
the morphological, molecular, and biochemical lev-
els.4,27,29,30 mtTFA is a critical transcription factor in
regulation of mitochondrial genes, proteins, and func-
tions. Indeed, mtTFA knockout mice display decreased
expression of mitochondrial genes and protein, as well
as mitochondrial dysfunction.31 Our data document
that there was decreased mtTFA expression in Ren2
livers compared with SD controls, restored by in vivo
AT1R blockade or antioxidant treatment.
Our findings also suggest that these deleterious ef-
fects of ANG II on hepatic mitochondria are mediated by
increased ROS generation. Our results indicate that both
increased activity of NADPH oxidase18 and decreased
activity of cytosolic Cu-ZnSOD (Figure 1E) contribute to
mitochondrial oxidative stress in the Ren2 livers. Exces-
sive ROS formation causes lipid peroxidation and release
of reactive aldehydes such as 4-HNE. Lipid peroxidation
has been shown to increase mitochondrial permeability,
cause mtDNA depletion, and reduce gene transcription
and peptide synthesis.32–34 There is also evidence that
4-HNE inactivates mitochondrial respiratory chain and
Figure 5. Effects of valsartan and tempol on hepatic mitochondrial indices
and -oxidation. A: Representative Western blot for cytochrome c (top) and
bar graph for densitometry analysis (bottom). B: MTCO1 mRNA expression
(normalized to GAPDH). C: Representative Western blot for MTCO1 (top)
and bar graph for densitometry analysis (bottom). D: mtTFA mRNA expres-
sion (normalized with GAPDH). E: Representative Western blot for mtTFA
(top) and bar graph for densitometry analysis (bottom). F: Activity of
-HAD and citrate synthase. G: The percentage of palmitate oxidized com-
pletely to CO2. The results are mean  SEM for five rats for each group, *P 
0.05 RV or RT versus RC. **P  0.01 RV or RT versus RC.
Figure 6. Effects of valsartan and tempol on hepatic lipogenic enzymes and
transcription factors. Representative Western blot (top) and bar graphs (bot-
tom) showed protein expression of active SREBP-1c (A), ChREBP (B), ACC1
(C), and FAS (D). The results are mean  SEM for five rats for each group.
There were no significant differences between groups (P  0.05).
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hampers electron flow of mitochondrial respiratory
chain.32–36 Inhibition/damage of mitochondrial respira-
tory chain complexes in turn further increases mitochon-
drial ROS production and accelerates mitochondrial ox-
idative stress.37–39 The mechanisms for inactivation of
mitochondrial respiratory chain complexes are possibly
via tyrosine nitration.40 In this regard, 4-HNE levels from
Ren2 hepatic mitochondria were dramatically increased
compared with SD livers (Figure 1D), and were sub-
stantially attenuated after valsartan or tempol treatment
(Figure 4A).
Increased de novo fatty acid synthesis can also lead to
hepatic steatosis. ACC1 and FAS are the key enzymes for
de novo fatty acid syntheses and are mainly regulated by
the transcription factors SREBP-1c and ChREBP.41,42
Mice overexpressing SREBP-1c in the liver exhibit in-
creased expression of FAS and develop fatty liver dis-
ease.32 Liver-specific inhibition of ChREBP markedly de-
creases expression of ACC and FAS and attenuates
hepatic steatosis in ob/ob mice.31 SREBP-1c and
ChREBP are inactive in the cytosol. When SREBP-1c (125
kDa) is cleaved by SREBP cleavage-activating protein
(SCAP) via proteolytic processing, an active fragment (68
kDa) is generated. Regulation for ChREBP activation re-
mains unclear, possibly through a mechanism of phos-
phorylation/dephosphorylation. Activated SREBP-1c and
ChREBP translocate into the nucleus and regulate the
expression of FAS and ACC1. Interestingly, there were no
differences in the protein levels of active SREBP-1c and
ChREBP between SD controls, untreated Ren2, and val-
sartan- or tempol-treated Ren2 rats (Figure 3, A and C,
and Figure 6, A and B). Immunostaining revealed that
SREBP-1c and ChREBP were predominately located in
the cytoplasm with a similar staining pattern among SD
controls, untreated Ren2, and treated Ren2 rats. ACC
and FAS are the major enzymes that directly promote
fatty acid synthesis. ACC1 catalyzes the carboxylation of
acetyl-CoA to malonyl-CoA, which is converted into
palmitate by FAS. There were no differences in the pro-
tein expression levels of ACC and FAS between SD con-
trols, untreated Ren2, and valsartan- or tempol-treated
Ren2 rats (Figure 3, E and F, and Figure 6, C and D).
These results suggest that lipogenic pathway is not a
contributor to ANG II-induced NAFLD in the Ren2 rat
model.
In summary, we report here, for the first time, that
elevated endogenous ANG II causes hepatic mitochon-
drial oxidative damage and impairs mitochondrial fatty
acid -oxidation contributing to the development of he-
patic steatosis.
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